Alnylam Pharmaceuticals, Inc. (ALNY) Position Boosted by Aperio Group LLC

Aperio Group LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,407 shares of the biopharmaceutical company’s stock after purchasing an additional 2,695 shares during the quarter. Aperio Group LLC’s holdings in Alnylam Pharmaceuticals were worth $2,049,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in ALNY. Point72 Asset Management L.P. boosted its position in shares of Alnylam Pharmaceuticals by 49.4% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,356,408 shares of the biopharmaceutical company’s stock valued at $133,593,000 after purchasing an additional 448,362 shares during the period. American Century Companies Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $42,128,000. Baillie Gifford & Co. boosted its position in shares of Alnylam Pharmaceuticals by 10.4% in the 2nd quarter. Baillie Gifford & Co. now owns 4,231,881 shares of the biopharmaceutical company’s stock valued at $416,798,000 after purchasing an additional 397,668 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Alnylam Pharmaceuticals by 333.0% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 302,695 shares of the biopharmaceutical company’s stock valued at $29,812,000 after purchasing an additional 232,782 shares during the period. Finally, Federated Investors Inc. PA boosted its position in shares of Alnylam Pharmaceuticals by 50.4% in the 2nd quarter. Federated Investors Inc. PA now owns 603,250 shares of the biopharmaceutical company’s stock valued at $59,414,000 after purchasing an additional 202,207 shares during the period. Institutional investors and hedge funds own 90.37% of the company’s stock.

In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 2,500 shares of the firm’s stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $120.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief operating officer now directly owns 1,916 shares in the company, valued at approximately $229,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.30% of the company’s stock.

ALNY has been the subject of a number of recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $149.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, August 6th. JMP Securities set a $198.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 28th. Piper Jaffray Companies reiterated an “overweight” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 23rd. BMO Capital Markets decreased their price target on Alnylam Pharmaceuticals from $125.00 to $124.00 and set an “outperform” rating for the company in a research report on Tuesday, October 16th. Finally, Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $93.00 to $87.00 and set an “equal weight” rating for the company in a research report on Friday, September 28th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $142.94.

Shares of NASDAQ ALNY opened at $73.04 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $71.85 and a one year high of $153.99. The stock has a market cap of $8.69 billion, a price-to-earnings ratio of -13.48 and a beta of 2.54. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.22 and a quick ratio of 13.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.02) by ($0.41). Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The business had revenue of $2.07 million for the quarter, compared to analyst estimates of $22.66 million. During the same quarter in the previous year, the business posted ($1.34) earnings per share. The company’s revenue was down 87.9% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.28 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://sportsperspectives.com/2018/11/09/alnylam-pharmaceuticals-inc-alny-position-boosted-by-aperio-group-llc.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

See Also: Preferred Stock

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply